At these two seminars you will hear about the two techniques of electrosynthesis and photoredoxchemistry, used more and more today by organic chemists. We will get some background information to the techniques and examples from how it is used in Helena’s and Markus’ labs. After the seminars we hope that you better understand when the […]
A half day dedicated to kinases in drug discovery organized by SciLifeLab DDD in collaboration with AstraZeneca. Kinases continue to attract much attention in drug discovery. Since the first compounds were launched in 2001 the learning curve of how to tackle different challenges has been steep. At the symposium we hope to give a broad […]
The DDD platform at SciLifeLab supports academic drug discovery project with expertise and technical capabilities. We have, for example, platforms to develop small molecule drugs, therapeutic antibodies, oligonucleotide therapeutics, proximity-inducing agents such as bispecific antibodies and PROTACs. In this call, the Drug Discovery and Development Platform (DDD) at SciLifeLab is looking for new pilot project […]
The chemical biology unit (CBCS) and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects. CBCS is looking for projects in Chemical Biology which includes assay development for small molecule screening and profiling, as well as enabling chemistry. For more information, please visit www.cbcs.se. The DDD platform has a call looking […]
Pandemic preparedness and the generation of SARS-CoV-2 inhibitors - A new exit from SciLifeLab Drug Discovery and Development platform
Join us for an exciting webinar delving into the topic of target validation in academic drug discovery. Discover strategies for effective target validation from our experts. Register now for our joint webinar with Karolinska Institutet and SciLifeLab Drug Discovery & Development and secure your spot
Drug Discovery Seminars: Catalyzing Confidence: A Novel Strategy for Enhancing DEL Hit Validation in Drug Discovery Presenter: Dr Stefan Geschwindner, PhD, Director Biophysics, AstraZeneca, Mölndal, Sweden Host: Pauliina Turunen, Unit Target Protein Engineering (TPE), SciLifeLab DDD Abstract In the realm of drug discovery, validating hits derived from DNA-encoded library (DEL) screening is an indispensable step. […]
The Chemical Biology and Genome Engineering platform and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects support. The Chemical Biology unit looks projects proposals including including assay development, small molecule screening, drug profiling, and medicinal and computational chemistry. For more information, please visit www.cbcs.se. The Chemical Biology and Genome Engineering […]
Learnings from the SciLifeLab model for drug discovery research, ten years perspective This symposium is part of the 10 year anniversary of the Drug Development and Discovery Platform at SciLifeLab. Translational research as a boost for Swedish Life Science: Learnings from the SciLifeLab model for drug discovery research, ten years perspective Program
This presentation will describe this workflow and discuss considerations for various ONT classes, emphasizing the importance of ONT-specific factors such as chemistry, delivery systems, and tissue distribution in OffT evaluation. It will also cover strategies for experimental verification and risk assessment and discuss the potential of machine learning models to enhance OffT prediction.
The seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE, that will train 48 future leaders in life sciences. The program focuses on innovative, fundamental and translational research carried out in supportive and diverse academic and industrial environments, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to […]
This presentation will provide an overview of the selection and screening processes, as well as future challenges for antibody-based drugs. It will be exemplified with data from one of Alligator Bioscience's bispecific antibody drug candidates, ATOR-4066.
